This invention is directed to β-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The β-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.

Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.

The present invention relates to a nanoparticle comprising a polymer, α-Galactosylceramide (α-GalCer) and chitosan. The invention also relates to multivalent immunogenic compositions. The invention has particular use as a pulmonary vaccine.

The present invention relates to immune-stimulating compositions comprising an immunestimulating compound covalently or non-convalently linked to glycogen-based nanoparticles. The immune stimulating compound may be a TLR agonist, dietary nucleotide, or combination thereof. The compositions can elicit a stronger, more robust, localized (intestine) and systemic immune response when delivered orally to aquatic species, than non-glycogen bound agonists and/or molecules.

The present disclosure provides nanostructures (e.g., monolayer or bilayer nanostructures) comprising porphyrins with cobalt chelated thereto such that the cobalt metal resides within monolayer or bilayer in the porphyrin macrocycle. The nanostructures can have presentation molecules comprising epitopes from microorganisms with a histidine tag attached thereto, such that at least a part of the his-tag is within the monolayer or bilayer and coordinated to the cobalt metal core and the presentation molecules are exposed to the outside of the nanostructures. The nanostructures can further comprise a cargo. The nanostructures can be used to deliver the cargo to an individual.

Preparation of hyaluronic acid based vaccines and a prophylactic or therapeutic method includes vaccinating a patient with hyaluronic acid.

The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) harboring an immunogenic amount of at least one vaccinal target molecule, with or without adjuvant. Specifically, Applicants discovered a combination of the composition of the liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and the manufacturing conditions for the dosage forms that can produce a freeze dried sublingual dosage form having physical robustness, particle and antigen integrity and stability.

The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject

Compositions comprising an antigen, a carbohydrate, and a metabolizable oil, methods of administering such compositions to a subject, methods of making such compounds, and related compositions, methods, and uses.

The present invention relates to a yeast-derived polysaccharide inducing Treg cells and a use thereof and, more particularly, to a polysaccharide comprising mannan and β-glucan, an composition for immunomodulation comprising the polysaccharide as an active ingredient, a pharmaceutical composition or food comprising the polysaccharide as an active ingredient for prevention or treatment of immune disease or inflammatory disease, a method for preparation of regulatory T cells by using the polysaccharide, a cell therapeutic agent comprising the regulatory T cells prepared by the preparation method as an active ingredient, and a treatment method using same. Even at a low dose, the novel polysaccharide according to the present invention allows the production of tolerogenic antigen presenting cells through the β-glucan and mannan structure retained therein, whereby the novel polysaccharide can induce the differentiation or production of antigen-specific regulatory T cells (Treg cells) to modulate the target immune system with low adverse effects. Therefore, MGCP and the Treg cells induced by the polysaccharide are effective for preventing or treating immune disease or inflammatory disease.